(NASDAQ: SGMT) Sagimet Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.75%.
Sagimet Biosciences's earnings in 2026 is -$47,079,000.On average, 14 Wall Street analysts forecast SGMT's earnings for 2026 to be -$71,799,460, with the lowest SGMT earnings forecast at -$79,799,279, and the highest SGMT earnings forecast at -$62,655,922. On average, 14 Wall Street analysts forecast SGMT's earnings for 2027 to be -$83,901,750, with the lowest SGMT earnings forecast at -$112,693,638, and the highest SGMT earnings forecast at -$25,453,968.
In 2028, SGMT is forecast to generate -$95,227,056 in earnings, with the lowest earnings forecast at -$130,359,127 and the highest earnings forecast at -$41,770,615.